Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validation of the Online Collaborative Ocular Tuberculosis Study Calculator for Tubercular Uveitis.
Zhang L, Rojas-Carabali W, Choo SS, Thng ZX, Lim YH, Lee B, Jun SW, Patnaik G, Biswas J, Agarwal A, Testi I, Mahajan S, Kempen JH, Smith JR, McCluskey P, Kon OM, Nguyen QD, Pavesio C, Gupta V, Agrawal R; Collaborative Ocular Tuberculosis Study (COTS) Group. Zhang L, et al. JAMA Ophthalmol. 2024 Dec 1;142(12):1140-1148. doi: 10.1001/jamaophthalmol.2024.4567. JAMA Ophthalmol. 2024. PMID: 39480402
Use of immunomodulatory treatment for non-infectious uveitis: an International Ocular Inflammation Society report of real-world practice.
Branford JA, Bodaghi B, Ferreira LB, McCluskey PJ, Thorne JE, Matthews JM; International Study Group for Systemic Immunomodulatory Drug Treatment of Non‐Infectious Uveitis; Smith JR. Branford JA, et al. Br J Ophthalmol. 2024 Nov 1:bjo-2024-326239. doi: 10.1136/bjo-2024-326239. Online ahead of print. Br J Ophthalmol. 2024. PMID: 39472042
Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration.
Teo KYC, Eldem B, Joussen A, Koh A, Korobelnik JF, Li X, Loewenstein A, Lövestam-Adrian M, Navarro R, Okada AA, Pearce I, Rodríguez F, Wong D, Wu L, Zur D, Zarranz-Ventura J, Mitchell P, Chaudhary V, Lanzetta P. Teo KYC, et al. Among authors: okada aa. Eye (Lond). 2024 Oct 8. doi: 10.1038/s41433-024-03370-0. Online ahead of print. Eye (Lond). 2024. PMID: 39379523 Review.
One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan.
Mukai R, Kataoka K, Tanaka K, Miyara Y, Maruko I, Nakayama M, Watanabe Y, Yamamoto A, Wakatsuki Y, Onoe H, Wakugawa S, Terao N, Hasegawa T, Kawai M, Maruko R, Itagaki K, Honjo J, Okada AA, Mori R, Koizumi H, Iida T, Sekiryu T. Mukai R, et al. Among authors: okada aa. Sci Rep. 2024 May 22;14(1):11681. doi: 10.1038/s41598-024-62559-1. Sci Rep. 2024. PMID: 38778065 Free PMC article.
Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial.
Koizumi H, Gomi F, Tsujikawa A, Honda S, Mori R, Ochi H, Iwasaki K, Okada AA; TENAYA and LUCERNE Investigators. Koizumi H, et al. Among authors: okada aa. Graefes Arch Clin Exp Ophthalmol. 2024 Aug;262(8):2439-2448. doi: 10.1007/s00417-024-06377-1. Epub 2024 Mar 14. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 38483611 Free PMC article. Clinical Trial.
INCIDENCE AND RISK FACTORS OF INTRAOCULAR INFLAMMATION AFTER BROLUCIZUMAB TREATMENT IN JAPAN: A Multicenter Age-Related Macular Degeneration Study.
Inoda S, Takahashi H, Maruyama-Inoue M, Ikeda S, Sekiryu T, Itagaki K, Matsumoto H, Mukai R, Nagai Y, Ohnaka M, Kusuhara S, Miki A, Okada AA, Nakayama M, Nishiguchi KM, Takeuchi J, Mori R, Tanaka K, Honda S, Kohno T, Koizumi H, Miyara Y, Inoue Y, Takana H, Iida T, Maruko I, Hayashi A, Ueda-Consolvo T, Yanagi Y. Inoda S, et al. Among authors: okada aa. Retina. 2024 Apr 1;44(4):714-722. doi: 10.1097/IAE.0000000000004009. Retina. 2024. PMID: 38016089
Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration.
Kataoka K, Itagaki K, Hashiya N, Wakugawa S, Tanaka K, Nakayama M, Yamamoto A, Mukai R, Honjyo J, Maruko I, Kawai M, Miyara Y, Terao N, Wakatsuki Y, Onoe H, Mori R, Koizumi H, Sekiryu T, Iida T, Okada AA; for Japan AMD Research Consortium (JARC). Kataoka K, et al. Among authors: okada aa. Graefes Arch Clin Exp Ophthalmol. 2024 Jan;262(1):43-51. doi: 10.1007/s00417-023-06222-x. Epub 2023 Sep 5. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 37668741
The Infectious Uveitis Treatment Algorithm Network (TITAN) Report 2-global current practice patterns for the management of Cytomegalovirus anterior uveitis.
Thng ZX, Putera I, Testi I, Chan K, Westcott M, Chee SP, Dick AD, Kempen JH, Bodaghi B, Thorne JE, Barisani-Asenbauer T, de Smet MD, Smith JR, McCluskey P, La Distia Nora R, Jabs DA, de Boer JH, Sen HN, Goldstein DA, Khairallah M, Davis JL, Rosenbaum JT, Jones NP, Nguyen QD, Pavesio C, Agrawal R, Gupta V; TITAN consensus guidelines group. Thng ZX, et al. Eye (Lond). 2024 Jan;38(1):68-75. doi: 10.1038/s41433-023-02631-8. Epub 2023 Jul 7. Eye (Lond). 2024. PMID: 37419958 Free PMC article.
196 results